Pfizer to Present Oncology Data at ASCO 2023 Annual Meeting
Pfizer will present data across its oncology portfolio and pipeline at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data covers over 15 therapies across 10+ cancer types.
New York – Pfizer Inc. announced it will present data from its oncology portfolio and pipeline at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, held from June 2 to June 6.
The presentations will include new data from pivotal trials supporting regulatory reviews for three potential therapies, with anticipated decisions this year for treatments in multiple myeloma, prostate cancer, and non-small cell lung cancer. The company will also present clinical data for six early-stage pipeline assets.
"At ASCO, Pfizer will present new data across the four key areas of our industry-leading portfolio – breast cancer, genitourinary cancer, hematology, and precision medicine – and for the first time, first-in-human data for some of our most exciting pipeline medicines," said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology and Rare Disease, Pfizer Global Product Development.
Pfizer's oncology portfolio includes 24 approved medicines, with over 30 programs in clinical development. The company expects regulatory decisions for three of these potential therapies this year, aiming to advance its oncology innovation.